Arrowhead Historical Income Statement

ARWR Stock

USD 24.44 0.31 1.28%

Historical analysis of Arrowhead Pharmaceuticals income statement accounts such as Interest Expense of 20 M, Selling General Administrative of 79.1 M or Selling And Marketing Expenses of 8.2 B can show how well Arrowhead Pharmaceuticals performed in making a profits. Evaluating Arrowhead Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Arrowhead Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Arrowhead Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arrowhead Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

About Arrowhead Income Statement Analysis

Arrowhead Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Arrowhead Pharmaceuticals shareholders. The income statement also shows Arrowhead investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Arrowhead Pharmaceuticals Income Statement Chart

Arrowhead Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Arrowhead's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Arrowhead Pharmaceuticals revenue and expense. Arrowhead Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At this time, Arrowhead Pharmaceuticals' Income Tax Expense is relatively stable compared to the past year. As of 05/04/2024, Research Development is likely to grow to about 426.5 M, while Selling General Administrative is likely to drop slightly above 79.1 M.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit Cost Of Revenue

Total Revenue

Total revenue comprises all receipts Arrowhead Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Arrowhead Pharmaceuticals minus its cost of goods sold. It is profit before Arrowhead Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Cost Of Revenue

Cost of Revenue is found on Arrowhead Pharmaceuticals income statement and represents the costs associated with goods and services Arrowhead Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Arrowhead Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Income Tax Expense is relatively stable compared to the past year. As of 05/04/2024, Research Development is likely to grow to about 426.5 M, while Selling General Administrative is likely to drop slightly above 79.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	243.2M	228.2M	262.5M	275.6M
Total Revenue	243.2M	240.7M	276.8M	290.7M

Gross Profit Total Revenue

Arrowhead Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Discontinued Operations	Net Income From Continuing Ops	Non Operating Income Net Other	Minority Interest	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		-0.11	0.86	0.48	0.94	0.94	0.98	-0.83	-0.83	-0.81	-0.33	0.98	-0.82	0.39	-0.82	0.44	0.98	-0.34	-0.82	0.37	0.85	-0.26	0.88	0.86	-0.25	0.86
Interest Expense	-0.11		-0.12	0.08	0.02	0.04	-0.14	0.33	0.32	0.33	-0.2	-0.14	0.37	0.5	0.37	-0.31	-0.14	-0.13	0.37	-0.05	-0.19	-0.05	-0.27	-0.05	0.72	-0.23
Selling General Administrative	0.86	-0.12		0.43	0.84	0.84	0.9	-0.88	-0.88	-0.87	-0.29	0.9	-0.86	0.49	-0.86	0.38	0.87	-0.37	-0.86	0.37	0.56	-0.13	0.83	0.59	0.02	0.83
Selling And Marketing Expenses	0.48	0.08	0.43		0.38	0.38	0.43	-0.4	-0.39	-0.39	0.24	0.43	-0.4	0.1	-0.39	0.18	0.41	-0.97	-0.37	-0.07	0.31	0.02	0.3	0.31	-0.04	0.28
Total Revenue	0.94	0.02	0.84	0.38		1.0	0.95	-0.68	-0.69	-0.67	-0.51	0.95	-0.67	0.46	-0.67	0.46	0.95	-0.24	-0.68	0.31	0.78	-0.28	0.89	0.86	-0.1	0.83
Gross Profit	0.94	0.04	0.84	0.38	1.0		0.94	-0.68	-0.68	-0.66	-0.52	0.94	-0.66	0.47	-0.66	0.45	0.95	-0.24	-0.67	0.31	0.76	-0.28	0.88	0.85	-0.07	0.83
Other Operating Expenses	0.98	-0.14	0.9	0.43	0.95	0.94		-0.87	-0.87	-0.86	-0.38	1.0	-0.86	0.37	-0.86	0.47	1.0	-0.28	-0.87	0.35	0.84	-0.18	0.91	0.87	-0.24	0.89
Operating Income	-0.83	0.33	-0.88	-0.4	-0.68	-0.68	-0.87		1.0	1.0	0.12	-0.87	1.0	-0.24	1.0	-0.38	-0.85	0.3	1.0	-0.35	-0.7	0.0	-0.77	-0.64	0.29	-0.83
Ebit	-0.83	0.32	-0.88	-0.39	-0.69	-0.68	-0.87	1.0		1.0	0.12	-0.87	0.99	-0.28	1.0	-0.36	-0.85	0.3	0.99	-0.39	-0.69	-0.02	-0.76	-0.63	0.28	-0.83
Ebitda	-0.81	0.33	-0.87	-0.39	-0.67	-0.66	-0.86	1.0	1.0		0.1	-0.86	1.0	-0.26	1.0	-0.36	-0.84	0.29	0.99	-0.38	-0.68	-0.03	-0.75	-0.61	0.28	-0.82
Cost Of Revenue	-0.33	-0.2	-0.29	0.24	-0.51	-0.52	-0.38	0.12	0.12	0.1		-0.38	0.11	-0.27	0.11	-0.38	-0.39	-0.3	0.12	0.12	-0.3	0.49	-0.37	-0.48	-0.23	-0.43
Total Operating Expenses	0.98	-0.14	0.9	0.43	0.95	0.94	1.0	-0.87	-0.87	-0.86	-0.38		-0.86	0.37	-0.86	0.47	1.0	-0.28	-0.87	0.35	0.84	-0.18	0.91	0.87	-0.24	0.89
Income Before Tax	-0.82	0.37	-0.86	-0.4	-0.67	-0.66	-0.86	1.0	0.99	1.0	0.11	-0.86		-0.18	1.0	-0.41	-0.85	0.3	1.0	-0.31	-0.71	0.01	-0.77	-0.64	0.34	-0.83
Total Other Income Expense Net	0.39	0.5	0.49	0.1	0.46	0.47	0.37	-0.24	-0.28	-0.26	-0.27	0.37	-0.18		-0.19	-0.29	0.36	-0.11	-0.18	0.72	0.04	0.09	0.18	0.19	0.6	0.28
Net Income	-0.82	0.37	-0.86	-0.39	-0.67	-0.66	-0.86	1.0	1.0	1.0	0.11	-0.86	1.0	-0.19		-0.41	-0.85	0.3	1.0	-0.31	-0.71	0.01	-0.77	-0.64	0.33	-0.83
Income Tax Expense	0.44	-0.31	0.38	0.18	0.46	0.45	0.47	-0.38	-0.36	-0.36	-0.38	0.47	-0.41	-0.29	-0.41		0.48	-0.09	-0.41	-0.35	0.45	-0.2	0.61	0.47	-0.34	0.48
Research Development	0.98	-0.14	0.87	0.41	0.95	0.95	1.0	-0.85	-0.85	-0.84	-0.39	1.0	-0.85	0.36	-0.85	0.48		-0.25	-0.85	0.34	0.87	-0.19	0.91	0.89	-0.27	0.89
Discontinued Operations	-0.34	-0.13	-0.37	-0.97	-0.24	-0.24	-0.28	0.3	0.3	0.29	-0.3	-0.28	0.3	-0.11	0.3	-0.09	-0.25		0.27	0.12	-0.12	-0.06	-0.16	-0.13	-0.08	-0.18
Net Income From Continuing Ops	-0.82	0.37	-0.86	-0.37	-0.68	-0.67	-0.87	1.0	0.99	0.99	0.12	-0.87	1.0	-0.18	1.0	-0.41	-0.85	0.27		-0.31	-0.72	0.01	-0.78	-0.65	0.35	-0.84
Non Operating Income Net Other	0.37	-0.05	0.37	-0.07	0.31	0.31	0.35	-0.35	-0.39	-0.38	0.12	0.35	-0.31	0.72	-0.31	-0.35	0.34	0.12	-0.31		0.19	0.32	0.23	0.18	0.01	0.28
Minority Interest	0.85	-0.19	0.56	0.31	0.78	0.76	0.84	-0.7	-0.69	-0.68	-0.3	0.84	-0.71	0.04	-0.71	0.45	0.87	-0.12	-0.72	0.19		-0.19	0.76	0.96	-0.58	0.77
Non Recurring	-0.26	-0.05	-0.13	0.02	-0.28	-0.28	-0.18	0.0	-0.02	-0.03	0.49	-0.18	0.01	0.09	0.01	-0.2	-0.19	-0.06	0.01	0.32	-0.19		-0.2	-0.18	-0.06	-0.21
Tax Provision	0.88	-0.27	0.83	0.3	0.89	0.88	0.91	-0.77	-0.76	-0.75	-0.37	0.91	-0.77	0.18	-0.77	0.61	0.91	-0.16	-0.78	0.23	0.76	-0.2		0.77	-0.36	0.84
Interest Income	0.86	-0.05	0.59	0.31	0.86	0.85	0.87	-0.64	-0.63	-0.61	-0.48	0.87	-0.64	0.19	-0.64	0.47	0.89	-0.13	-0.65	0.18	0.96	-0.18	0.77		-0.41	0.78
Net Interest Income	-0.25	0.72	0.02	-0.04	-0.1	-0.07	-0.24	0.29	0.28	0.28	-0.23	-0.24	0.34	0.6	0.33	-0.34	-0.27	-0.08	0.35	0.01	-0.58	-0.06	-0.36	-0.41		-0.29
Reconciled Depreciation	0.86	-0.23	0.83	0.28	0.83	0.83	0.89	-0.83	-0.83	-0.82	-0.43	0.89	-0.83	0.28	-0.83	0.48	0.89	-0.18	-0.84	0.28	0.77	-0.21	0.84	0.78	-0.29

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	5.9M	8.3M	10.4M	12.5M	14.4M	15.1M
Interest Expense	9.2B	6.1M	5.0M	18.3M	21.1M	20.0M
Selling General Administrative	52.3M	81.0M	124.4M	92.5M	83.3M	79.1M
Total Revenue	88.0M	138.3M	243.2M	240.7M	276.8M	290.7M
Gross Profit	88.0M	138.3M	243.2M	228.2M	262.5M	275.6M
Other Operating Expenses	181.2M	287.3M	421.7M	445.7M	512.6M	538.2M
Operating Income	(93.2M)	(149.0M)	(178.5M)	(205.0M)	(184.5M)	(175.3M)
Ebit	(93.2M)	(149.0M)	(178.5M)	(200.7M)	(180.6M)	(171.6M)
Ebitda	(87.2M)	(140.8M)	(168.1M)	(188.2M)	(169.3M)	(160.9M)
Total Operating Expenses	181.2M	287.3M	421.7M	445.7M	512.6M	538.2M
Income Before Tax	(84.6M)	(140.8M)	(172.7M)	(206.5M)	(185.8M)	(176.5M)
Total Other Income Expense Net	8.6M	8.2M	5.8M	1.5M	1.8M	888.4K
Net Income	(84.6M)	(140.8M)	(176.5M)	(205.3M)	(184.7M)	(175.5M)
Research Development	128.9M	206.3M	297.3M	353.2M	406.2M	426.5M
Net Income From Continuing Ops	(84.6M)	(140.8M)	(172.7M)	(209.3M)	(188.3M)	(178.9M)
Net Income Applicable To Common Shares	(84.6M)	(140.8M)	(176.1M)	(205.3M)	(184.7M)	(175.5M)
Net Interest Income	9.2M	6.1M	5.0M	(3.0M)	(3.5M)	(3.3M)
Reconciled Depreciation	5.9M	8.3M	10.4M	12.5M	14.4M	8.0M

Arrowhead Pharmaceuticals Investors Sentiment

The influence of Arrowhead Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Arrowhead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Arrowhead Pharmaceuticals' public news can be used to forecast risks associated with an investment in Arrowhead. The trend in average sentiment can be used to explain how an investor holding Arrowhead can time the market purely based on public headlines and social activities around Arrowhead Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Arrowhead Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Arrowhead Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Arrowhead Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Arrowhead Pharmaceuticals.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arrowhead Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arrowhead Pharmaceuticals' short interest history, or implied volatility extrapolated from Arrowhead Pharmaceuticals options trading.

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Arrowhead Stock

0.83

VRAX

Virax Biolabs Group Fiscal Year End 12th of June 2024

Pair Corr

Moving against Arrowhead Stock

0.68	LIXT	Lixte Biotechnology Earnings Call This Week	Pair Corr
0.56	INDP	Indaptus Therapeutics Financial Report 9th of May 2024	Pair Corr
0.54	GBIO	Generation BioCo Financial Report 8th of May 2024	Pair Corr
0.43	ELVN	Enliven Therapeutics Trending	Pair Corr

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:

How To Invest In Arrowhead

Details

Is Arrowhead Stock a good investment?

Details

What is Arrowhead Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Arrowhead Stock analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	CEOs Directory Screen CEOs from public companies around the world
	Stocks Directory Find actively traded stocks across global markets
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities

Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.098

Earnings Share

(2.77)

Revenue Per Share

1.697

Quarterly Revenue Growth

(0.94)

Return On Assets

(0.25)

The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arrowhead Historical Income Statement

About Arrowhead Income Statement Analysis

Arrowhead Pharmaceuticals Income Statement Chart

Total Revenue

Gross Profit

Cost Of Revenue

Arrowhead Pharmaceuticals income statement Correlations

Arrowhead Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arrowhead Pharmaceuticals income statement Accounts

Arrowhead Pharmaceuticals Investors Sentiment

Pair Trading with Arrowhead Pharmaceuticals

Moving together with Arrowhead Stock

Moving against Arrowhead Stock

Complementary Tools for Arrowhead Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Research Development	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Discontinued Operations	- 0.97	Selling And Marketing Expenses
Ebit	- 0.88	Selling General Administrative
Operating Income	- 0.88	Selling General Administrative
Net Income From Continuing Ops	- 0.87	Total Operating Expenses
Total Operating Expenses	- 0.87	Ebit
Total Operating Expenses	- 0.87	Operating Income